[Long-term treatment of depressive syndromes with Psyton (author's transl)].
23 patients (in-patients and out-patients) with anxious-depressive symptoms were treated orally with the combination drug Psyton (nomifensine/clobazam) up to 6 months. Significant improvement of both anxiety and depression were observed by both the patients' and physician's assessment, particularly during the first month of treatment. Physical examination and laboratory investigations (weight, pulse rate, blood pressure, EKG, ophthalmology, blood and urine analysis, liver function tests) were not influenced by Psyton. Drug tolerance was good, and side effects observed in 39% of the patients were minimal and mainly occurred within 4 weeks after onset of treatment. There was no tendency to physical drug dependence during treatment and during a one-week placebo phase after discontinuation of Psyton. Hence, a long-term treatment of anxious depressive syndromes with this combination drug appears justified without development of drug dependence.
D000293:Adolescent; D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000078306:Clobazam; D003866:Depressive Disorder / Q000188:drug therapy*; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009627:Nomifensine / Q000627:therapeutic use*; D010919:Placebos; D019966:Substance-Related Disorders
D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; D004338:Drug Combinations; D007546:Isoquinolines; D010919:Placebos; D001569:Benzodiazepines; D009627:Nomifensine; D000078306:Clobazam; C035008:psyton
Langzeitbehandlung depressiver Syndrome mit Psyton.